Ryan Dillon

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

Richard L. Hengel, Timothy E. Ritter, Ramesh V Nathan et al. · Open Forum Infectious Diseases · 2020 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Patterns, Predictors, and Intercenter Variability in Empiric Gram-Negative Antibiotic Use Across 928 United States Hospitals

Katherine E Goodman, Jonathan Baghdadi, Laurence S. Magder et al. · Clinical Infectious Diseases · 2022 · 29 citations · Full text

Pharmacy, Internal Medicine, Antimicrobial Pharmacotherapy +15

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Shilpa Gupta, Yohann Loriot, Michiel S. van der Heijden et al. · The Lancet Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

Matthew I. Milowsky, Peter H. O’Donnell, Christopher Hoimes et al. · Journal of Clinical Oncology · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections

Aisling R. Caffrey, Haley J. Appaneal, J. Xin Liao et al. · Antibiotics · 2022 · 13 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +12